Teneliximab

Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion[1].

Product Specifications

CAS Number

[299423-37-3]

Product Name Alternative

BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/teneliximab.html

Purity

99.0

Solubility

10 mM in H2O

Smiles

[Teneliximab]

Molecular Weight

(146.06 kDa)

References & Citations

[1]Maria A Argiriadi, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20 (1) :29.|[2]Andrew B Adams, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005 Jan 1;174 (1) :542-50.